Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of TNM001 for prevention of RSV lower respiratory tract infection in high-risk infants
CTR20244435Phase 3Completed
- Sponsor
- Trinomab Pharmaceutical
- Start
- Nov 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of TNM001 in respiratory syncytial virus disease (RSV), sponsored by Trinomab Pharmaceutical. Started Nov 2024; status: completed.
02
Drugs
TNM001
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on CTR20244435.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244435.